902 related articles for article (PubMed ID: 19696226)
1. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.
Schrier RW
J Am Soc Nephrol; 2009 Sep; 20(9):1888-93. PubMed ID: 19696226
[TBL] [Abstract][Full Text] [Related]
2. Contribution of renal innervation to hypertension in rat autosomal dominant polycystic kidney disease.
Gattone VH; Siqueira TM; Powell CR; Trambaugh CM; Lingeman JE; Shalhav AL
Exp Biol Med (Maywood); 2008 Aug; 233(8):952-7. PubMed ID: 18480417
[TBL] [Abstract][Full Text] [Related]
3. Optimal care of autosomal dominant polycystic kidney disease patients.
Schrier RW
Nephrology (Carlton); 2006 Apr; 11(2):124-30. PubMed ID: 16669974
[TBL] [Abstract][Full Text] [Related]
4. Interpretation of renal volume in autosomal dominant polycystic kidney disease and relevant clinical implications.
Masoumi A; Elhassan E; Schrier RW
Iran J Kidney Dis; 2011 Jan; 5(1):1-8. PubMed ID: 21189426
[TBL] [Abstract][Full Text] [Related]
5. Hypertension and left ventricular hypertrophy in autosomal dominant polycystic kidney disease.
Ecder T; Schrier RW
Expert Rev Cardiovasc Ther; 2004 May; 2(3):369-74. PubMed ID: 15151483
[TBL] [Abstract][Full Text] [Related]
6. Autosomal dominant polycystic kidney disease: role of the renin-angiotensin system in raised blood pressure in progression of renal and cardiovascular disease.
Lawson CR; Doulton TW; MacGregor GA
J Renin Angiotensin Aldosterone Syst; 2006 Sep; 7(3):139-45. PubMed ID: 17094050
[TBL] [Abstract][Full Text] [Related]
7. Borderline hypertensive autosomal dominant polycystic kidney disease patients have enhanced production of renal dopamine. Normalization of renal haemodynamics by DOPA infusion.
Barendregt JN; Florijn KW; Muizert Y; Chang PC
Nephrol Dial Transplant; 1995; 10(8):1332-41. PubMed ID: 8538923
[TBL] [Abstract][Full Text] [Related]
8. [Blood pressure, functional and morphological study of kidneys in children with autosomal dominant polycystic kidney disease].
Seeman T; Vondrichová H; Strízová J; Sikut M; Janda J; Schärer K
Cas Lek Cesk; 1999 Mar; 138(6):178-84. PubMed ID: 10510532
[TBL] [Abstract][Full Text] [Related]
9. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
Zeltner R; Poliak R; Stiasny B; Schmieder RE; Schulze BD
Nephrol Dial Transplant; 2008 Feb; 23(2):573-9. PubMed ID: 17984104
[TBL] [Abstract][Full Text] [Related]
10. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease.
Chapman AB; Johnson A; Gabow PA; Schrier RW
N Engl J Med; 1990 Oct; 323(16):1091-6. PubMed ID: 2215576
[TBL] [Abstract][Full Text] [Related]
11. The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease.
Loghman-Adham M; Soto CE; Inagami T; Cassis L
Am J Physiol Renal Physiol; 2004 Oct; 287(4):F775-88. PubMed ID: 15187005
[TBL] [Abstract][Full Text] [Related]
12. Effect of enalapril on blood pressure, renal function, and the renin-angiotensin-aldosterone system in cats with autosomal dominant polycystic kidney disease.
Miller RH; Lehmkuhl LB; Smeak DD; DiBartola SP; Radin J
Am J Vet Res; 1999 Dec; 60(12):1516-25. PubMed ID: 10622161
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population.
Kelleher CL; McFann KK; Johnson AM; Schrier RW
Am J Hypertens; 2004 Nov; 17(11 Pt 1):1029-34. PubMed ID: 15533729
[TBL] [Abstract][Full Text] [Related]
14. Expression of components of the renin-angiotensin system in autosomal recessive polycystic kidney disease.
Loghman-Adham M; Soto CE; Inagami T; Sotelo-Avila C
J Histochem Cytochem; 2005 Aug; 53(8):979-88. PubMed ID: 15879580
[TBL] [Abstract][Full Text] [Related]
15. Hypertension in autosomal dominant polycystic kidney disease.
Chapman AB; Stepniakowski K; Rahbari-Oskoui F
Adv Chronic Kidney Dis; 2010 Mar; 17(2):153-63. PubMed ID: 20219618
[TBL] [Abstract][Full Text] [Related]
16. Temporal relationship between renal cyst development, hypertension and cardiac hypertrophy in a new rat model of autosomal recessive polycystic kidney disease.
Phillips JK; Hopwood D; Loxley RA; Ghatora K; Coombes JD; Tan YS; Harrison JL; McKitrick DJ; Holobotvskyy V; Arnolda LF; Rangan GK
Kidney Blood Press Res; 2007; 30(3):129-44. PubMed ID: 17446713
[TBL] [Abstract][Full Text] [Related]
17. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease.
Ecder T; Edelstein CL; Chapman AB; Johnson AM; Tison L; Gill EA; Brosnahan GM; Schrier RW
Nephrol Dial Transplant; 1999 May; 14(5):1113-6. PubMed ID: 10344347
[TBL] [Abstract][Full Text] [Related]
18. Hypertension and renal injury in experimental polycystic kidney disease.
Kennefick TM; Al-Nimri MA; Oyama TT; Thompson MM; Kelly FJ; Chapman JG; Anderson S
Kidney Int; 1999 Dec; 56(6):2181-90. PubMed ID: 10594794
[TBL] [Abstract][Full Text] [Related]
19. [The relation of hypertension, renal function and cardiovascular events in autosomal dominant polycystic kidney disease].
Idrizi A; Barbullushi M; Strakosha A; Kodra S; Thereska N; Zaimi E; Gjyzari A; Petrela E
G Ital Nefrol; 2007; 24(6):595-9. PubMed ID: 18278763
[TBL] [Abstract][Full Text] [Related]
20. ACE inhibitors, left ventricular mass and renal cyst growth in ADPKD.
Schrier RW
Pharmacol Res; 2016 Dec; 114():166-168. PubMed ID: 27794499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
